scispace - formally typeset
Open AccessJournal ArticleDOI

Reaching detection targets in familial hypercholesterolaemia: Comparison of identification strategies.

Reads0
Chats0
TLDR
Child-parent Cascade Screening is the fastest strategy for identifying FH in the population and is applicable to any country to close the FH detection gap.
About
This article is published in Atherosclerosis.The article was published on 2020-01-01 and is currently open access. It has received 26 citations till now. The article focuses on the topics: Population.

read more

Citations
More filters
Journal ArticleDOI

Heart Disease and Stroke Statistics—2022 Update: A Report From the American Heart Association

- 22 Feb 2022 - 
TL;DR: The American Heart Association, through its Statistics Committee, continuously monitors and evaluates sources of data on heart disease and stroke in the United States to provide the most current information available in the annual Statistical Update as discussed by the authors .
Journal ArticleDOI

Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association

- 21 Feb 2023 - 
TL;DR: The 2023 Statistical Update as mentioned in this paper provides the most up-to-date statistics related to heart disease, stroke, and cardiovascular risk factors including core health behaviors (smoking, physical activity, diet, and weight) and health factors (cholesterol, blood pressure, and glucose control) that contribute to cardiovascular health.
Journal ArticleDOI

Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association

- 21 Feb 2023 - 
TL;DR: The 2023 Statistical Update as mentioned in this paper provides the most up-to-date statistics related to heart disease, stroke, and cardiovascular risk factors including core health behaviors (smoking, physical activity, diet, and weight) and health factors (cholesterol, blood pressure, and glucose control) that contribute to cardiovascular health.

Delivery and Impact of the NHS Health Check in the First 8 Years

TL;DR: A systematic review and quantitative data synthesis as mentioned in this paper reviewed quantitative evidence on coverage (the proportion of eligible individuals who attend, uptake (proportion of invitees who attend), and impact of NHS Health Checks, and concluded that just under half (48.2%) of those invited have taken up the invitation.
Journal ArticleDOI

Advances, gaps and opportunities in the detection of familial hypercholesterolemia: overview of current and future screening and detection methods.

TL;DR: Investigation of familial hypercholesterolemia can be enhanced by optimizing current diagnostic algorithms, probing electronic health records with novel information technologies and integrating universal screening of children with cascade testing of parents and other relatives.
References
More filters
Journal ArticleDOI

Cost effectiveness of cascade testing for familial hypercholesterolaemia, based on data from familial hypercholesterolaemia services in the UK.

TL;DR: Cascade testing of relatives of those with suspected FH is highly cost effective, and Europe-wide high levels of undiagnosed FH, and associated morbidity and mortality, mean adoption of cascade services should yield substantial quality of life and survival gains.
Journal ArticleDOI

The evaluation of cascade testing for familial hypercholesterolemia.

TL;DR: Cascade testing is not a suitable method of population screening for FH, because a separate method of systematically identifying new FH index cases is required to achieve a reasonable level of FH detection in the population.
Journal ArticleDOI

Universal screening for familial hypercholesterolemia in children: The Slovenian model and literature review.

TL;DR: FH was confirmed in almost half of the referred children, detected through the universal screening for hypercholesterolemia, and one parent had highly probable FH.
Journal ArticleDOI

Genetic testing for familial hypercholesterolaemia is essential in individuals with high LDL cholesterol: who does it in the world?

TL;DR: Findings from Japan highlight that a genetic diagnosis of FH identifies individuals at higher risk of coronary artery disease than solely judged by the LDL cholesterol level alone, probably because the genetic diagnosis indicates a lifelong effect.
Journal ArticleDOI

Universal screening at age 1-2 years as an adjunct to cascade testing for familial hypercholesterolaemia in the UK: A cost-utility analysis.

TL;DR: Findings support implementation of universal cholesterol screening followed by diagnostic genetic testing and RCT for FH, under a UK conventional willingness-to-pay threshold.
Related Papers (5)

Reducing the Clinical and Public Health Burden of Familial Hypercholesterolemia: A Global Call to Action

Katherine Wilemon, +94 more
- 02 Jan 2020 - 
Frequently Asked Questions (12)
Q1. What have the authors contributed in "Reaching detection targets in familial hypercholesterolaemia; comparison of identification strategies" ?

In this paper, the authors developed a model to estimate the time to identify different proportions of FH in the population for the three identification strategies. 

Office for National Statistics (2017) data were used for population size [12], fertility rate [13], maternal age distribution [10] and the number of deaths per year [14] and WHO/UNICEF data for immunization coverage. [15] 

Child-parent Cascade Screening could identify 50% of all FH cases in about 17 years and 75% detection in about 30 years, after which most affected families would be known and Cascade Testing would continue as the main and highly cost-effective identification method. 

The method is self-limiting and can only be sustained if supported by a separate method to provide a steady and substantial number of unrelated index cases. [7] 

Based on the current efficacy of Cascade Testing (number of new per known cases identified), 5098 unrelated FH index cases would need to be found each year for Cascade Testing to reach the 25% target in 5 years. 

The current index case identification rate is 556 per year; doubling this to 1112 would still require 31 years to reach the 25% detection target. 

The results of this analysis show that the fastest strategy for closing the identification gap in FH is Child-parent Cascade Screening, an integration of universal screening in childhood, based on total cholesterol measurement supported by FH mutation testing during immunisation and subsequent Cascade Testing within mutation-positive families. 

Both child, and parent benefit from such screening, from life-style interventions and the timely introduction of drug therapy (principally statins); but the child benefits twice, once by reducing his/her own risk of premature ischaemic heart disease and again by avoiding the premature death of a parent. 

Child-parent Cascade Screening is a strategy that has been shown to be effective and affordable, costing about £980 per new FH case identified. [9] 

Sensitivity analyses were performed to examine the effect of doubling the efficacy of Cascade Testing (number of new per known cases identified) and increasing the uptake of Child-parent Screening by 10% points. 

Electronic health records in adults are a potential supplement to identifying new FH index cases but largely miss the preventive opportunity (median age at an NHS Health Check is about 60 years). [22] 

For Child-parent Cascade Screening each FH positive child also leads to the identification of their affected siblings (older siblings in the first two years of screening) and grandparent.